
Medicus Pharma and HelixNano sign MOU to co-develop thermostable, needle-free mRNA vaccines
05/08/2025
0:00
7:23
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce the signing of a non-binding Memorandum of Understanding (MoU) with biotechnology firm HelixNano, aimed at co-developing thermostable mRNA-based vaccines by combining their respective proprietary technologies.
The collaboration intends to merge HelixNano’s advanced mRNA vaccine platform with Medicus’ dissolvable microneedle array (MNA) delivery system, with the goal of creating needle-free, thermostable vaccines that can overcome cold-chain logistics, reduce distribution costs, and significantly enhance global accessibility.
Dr. Bokhari noted that both companies are in active negotiations to form a joint venture that will lead the co-development and commercialization of these next-generation vaccines. As part of the preliminary work, Medicus and HelixNano have agreed to begin research and production of clinical-grade mRNA vaccine-loaded MNAs for use in a Phase 1 clinical bridging study. This study will compare the safety and early efficacy of traditional intramuscular injection versus intradermal microneedle delivery using HelixNano’s HN-0001 vaccine candidate.
Bokhari stated, “Combining HelixNano’s potent mRNA vaccine science with our dissolvable microneedle array technology has the potential to redefine how vaccines are delivered worldwide—without needles, without refrigeration, and at scale. This could place us at the forefront of a paradigm shift in infectious disease prevention.”
The MoU formalizes the mutual intent to collaborate while both parties work to finalize the terms of the proposed joint venture.
#proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #UAEHealth #NonInvasiveTherapy #Doxorubicin #ClinicalTrials #HealthcareInnovation
D'autres épisodes de "Proactive - Interviews for investors"
Ne ratez aucun épisode de “Proactive - Interviews for investors” et abonnez-vous gratuitement à ce podcast dans l'application GetPodcast.